Network medicine, multimorbidity and the lung in the elderly

European Respiratory Journal

Volumn 44, Issue 3, 2014, Pages 775-788

  Faner, Rosa ^a,b   Cruz, Tamara ^a,b   López Giraldo, Alejandra ^a,b,c   Agustí, Alvar ^a,b,c,d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Fundació Investigació Sanitaria Illes Balears FISIB   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGING; ARTICLE; CELL DAMAGE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE ASSOCIATION; ENVIRONMENT; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MEDICINE; MORBIDITY; MULTIMORBIDITY; NETWORK MEDICINE; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMS BIOLOGY; UNITED STATES; BIOLOGICAL MODEL; COMPLICATION; GERIATRICS; LUNG; LUNG DISEASES; PATHOPHYSIOLOGY; PROCEDURES; RESPIRATION DISORDERS;

AGED; AGING; COMORBIDITY; GERIATRICS; HUMANS; LUNG; LUNG DISEASES; MODELS, BIOLOGICAL; RESPIRATION DISORDERS; SYSTEMS BIOLOGY;

EID: 84907211818     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00078714     Document Type: Article

References (75)

1. Rosenbaum L, Lamas D. Facing a "slow-motion disaster" - the UN meeting on noncommunicable diseases. N Engl J Med 2011; 365: 2345-2348.
2. Bousquet J, Anto JM, Sterk PJ, et al. Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med 2011; 3: 43.
3. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37-43.
4. Hidalgo CA, Blumm N, Barabási AL, et al. A dynamic network approach for the study of human phenotypes. PLoS Comput Biol 2009; 5: e1000353.
5. Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc 2007; 4: 522-525.
6. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
7. Faner R, Rojas M, MacNee W, et al. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 306-313.
8. Agustí AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-360.
9. Kirkwood TB. Understanding the odd science of aging. Cell 2005; 120: 437-447.
10. López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell 2013; 153: 1194-1217.
11. The right prevention and treatment for the right patient at the right time. Strategic Research Agenda for Innovative Medicines Initiative 2. Brussels, European Federation of Pharmaceutical Industries and Associations, 2014. www.efpia.eu/uploads/Modules/Documents/def-efpia-brochure-sra-a4-web.pdf
12. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-1648.
13. Kohansal R, Martinez-Camblor P, Agustí A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009; 180: 3-10.
14. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-212.
15. Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 549-555.
16. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
17. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65: 956-962.
18. Agustí A, Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2012; 9: 43-46.
19. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161.
20. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 2013; 1: 73-83.
21. Van Remoortel H, Hornikx M, Langer D, et al. Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 189: 30-38.
22. De Martinis M, Franceschi C, Monti D, et al. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005; 579: 2035-2039.
23. De Martinis M, Franceschi C, Monti D, et al. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 2006; 80: 219-227.
24. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483.
25. Galas DJ, Hood L. Systems biology and emerging technologies will catalyze the transition from reactive medicine to predictive, personalized, preventive and participatory (P4) medicine. IBC 2009; 1: 1-5.
26. Auffray C, Adcock IM, Chung KF, et al. An integrative systems biology approach to understanding pulmonary diseases. Chest 2010; 137: 1410-1416.
27. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
28. Collins FS, Green ED, Guttmacher AE, et al. A vision for the future of genomics research. Nature 2003; 422: 835-847.
29. Agustí A, Sobradillo P, Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med 2011; 183: 1129-1137.
30. Vanfleteren LE, Kocks JW, Stone IS, et al. Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax 2014; 69: 72-79.
31. Kitano H. Systems biology: a brief overview. Science 2002; 295: 1662-1664.
32. Barabási AL. Network medicine - from obesity to the "diseasome". N Engl J Med 2007; 357: 404-407.
33. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011; 12: 56-68.
34. Kitano H. Computational systems biology. Nature 2002; 420: 206-210.
35. Khoury MJ, Gwinn ML, Glasgow RE, et al. A population approach to precision medicine. Am J Prev Med 2012; 42: 639-645.
36. Carter GW, Galas DJ, Galitski T. Maximal extraction of biological information from genetic interaction data. PLoS Comput Biol 2009; 5: e1000347.
37. Bauer-Mehren A, Rautschka M, Sanz F, et al. DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks. Bioinformatics 2010; 26: 2924-2926.
38. Clermont G, Auffray C, Moreau Y, et al. Bridging the gap between systems biology and medicine. Genome Med 2009; 1: 88.
39. Kohl P, Crampin EJ, Quinn TA, et al. Systems biology: an approach. Clin Pharmacol Ther 2010; 88: 25-33.
40. Christakis NA, Fowler JH. The collective dynamics of smoking in a large social network. N Engl J Med 2008; 358: 2249-2258.
41. Agustí A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184: 507-513.
42. Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med 2007; 357: 370-379.
43. Goh KI, Cusick ME, Valle D, et al. The human disease network. Proc Natl Acad Sci USA 2007; 104: 8685-8690.
44. Barabási AL, Bonabeau E. Scale-free networks. Sci Am 2003; 288: 60-69.
45. Barabási AL. Scale-free networks: a decade and beyond. Science 2009; 325: 412-413.
46. Vázquez A, Dobrin R, Sergi D, et al. The topological relationship between the large-scale attributes and local interaction patterns of complex networks. Proc Natl Acad Sci USA 2004; 101: 17940-17945.
47. Rzhetsky A, Wajngurt D, Park N, et al. Probing genetic overlap among complex human phenotypes. Proc Natl Acad Sci USA 2007; 104: 11694-11699.
48. Han JD. An aging program at the systems level? Birth Defects Res C Embryo Today 2012; 96: 206-211.
49. Sozou PD, Kirkwood TB. A stochastic model of cell replicative senescence based on telomere shortening, oxidative stress, and somatic mutations in nuclear and mitochondrial DNA. J Theor Biol 2001; 213: 573-586.
50. Kenyon CJ. The genetics of ageing. Nature 2010; 464: 504-512.
51. Panowski SH, Wolff S, Aguilaniu H, et al. PHA-4/Foxa mediates diet-restriction-induced longevity of C. elegans. Nature 2007; 447: 550-555.
52. Houtkooper RH, Williams RW, Auwerx J. Metabolic networks of longevity. Cell 2010; 142: 9-14.
53. de Magalhães JP, Budovsky A, Lehmann G, et al. The human ageing genomic resources: online databases and tools for biogerontologists. Aging Cell 2009; 8: 65-72.
54. Xue H, Xian B, Dong D, et al. A modular network model of aging. Mol Syst Biol 2007; 3: 147.
55. Kirkwood TB. Systems biology of ageing and longevity. Philos Trans R Soc Lond B Biol Sci 2011; 366: 64-70.
56. Lee DS, Park J, Kay KA, et al. The implications of human metabolic network topology for disease comorbidity. Proc Natl Acad Sci USA 2008; 105: 9880-9885.
57. Park J, Lee DS, Christakis NA, et al. The impact of cellular networks on disease comorbidity. Mol Syst Biol 2009; 5: 262.
58. Hwang S, Son SW, Kim SC, et al. A protein interaction network associated with asthma. J Theor Biol 2008; 252: 722-731.
59. Menche J, Sharma A, Cho MH, et al. A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in chronic obstructive pulmonary disease. BMC Systems Biology 2014; 8: Suppl. 2, S8.
60. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model. Am J Respir Crit Care Med 2014; 189: 1161-1172.
61. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE). Eur Respir J 2008; 31: 869-873.
62. Vestbo J, Agustí A, Wouters EF, et al. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 2014; 189: 1022-1030.
63. Faner R, Tal-Singer R, Riley JH, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax 2014; 69: 666-672.
64. Agustí A, MacNeeW. The COPD control panel: towards personalised medicine in COPD. Thorax 2013; 68: 687-690.
65. McDonald VM, Higgins I, Wood LG, et al. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax 2013; 68: 691-694.
66. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728-735.
67. Agustí A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
68. Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107: 1376-1384.
69. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010; 36: 531-539.
70. Xie L, Wu M, Lin H, et al. An increased ratio of serum miR-21 to miR-181a levels is associated with the early pathogenic process of chronic obstructive pulmonary disease in asymptomatic heavy smokers. Mol Biosyst 2014; 10: 1072-1081.
71. Ezzie ME, Crawford M, Cho JH, et al. Gene expression networks in COPD: microRNA and mRNA regulation. Thorax 2012; 67: 122-131.
72. Turan N, Kalko S, Stincone A, et al. A systems biology approach identifies molecular networks defining skeletal muscle abnormalities in chronic obstructive pulmonary disease. PLoS Comput Biol 2011; 7: e1002129.
73. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999; 159: S1-S40.
74. Gea J, Agustí A, Roca J. Pathophysiology of muscle dysfunction in COPD. J Appl Physiol 2013; 114: 1222-1234.
75. Agustí A, Barberà JA, Wouters EF, et al. Lungs, bone marrow and adipose tissue. A network approach to the pathobiology of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 1396-1406.